Related Experiment Video
Updated: Jun 4, 2026
12:58
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Fidaxomicin versus vancomycin for Clostridium difficile infection
Thomas J Louie1, Mark A Miller, Kathleen M Mullane
1University of Calgary, Calgary, AB, Canada. thomas.louie@albertahealthservices.ca
The New England Journal of Medicine
|February 4, 2011
Summary
Fidaxomicin demonstrated noninferior clinical cure rates compared to vancomycin for Clostridium difficile infection. This new treatment significantly reduced infection recurrence, particularly in specific strain types.
Area of Science:
- Infectious Diseases
- Microbiology
- Clinical Pharmacology
Background:
- Clostridium difficile infection (CDI) presents significant morbidity and mortality.
- Recurrence rates following standard treatment (vancomycin or metronidazole) remain high.
- A phase 3 trial was conducted to evaluate fidaxomicin versus vancomycin for CDI treatment.
Purpose of the Study:
- To compare the efficacy and safety of fidaxomicin with vancomycin in treating C. difficile infection.
- To assess clinical cure rates and recurrence rates between the two treatment groups.
- To identify potential differences in outcomes based on bacterial strain types.
Main Methods:
- Adults with acute CDI and positive stool toxin tests were enrolled.
- Patients received either oral fidaxomicin (200 mg BID) or oral vancomycin (125 mg QID) for 10 days.
- Primary endpoint was clinical cure; secondary endpoints included recurrence and global cure rates.
Main Results:
- Clinical cure rates were noninferior for fidaxomicin compared to vancomycin in both intention-to-treat and per-protocol analyses.
- Fidaxomicin showed significantly lower recurrence rates (15.4% vs. 25.3% ITT; 13.3% vs. 24.0% PP).
- Reduced recurrence with fidaxomicin was notable in patients with non-North American Pulsed Field type 1 strains; adverse events were similar.
Conclusions:
- Fidaxomicin offers comparable clinical cure rates to vancomycin for C. difficile infection.
- Fidaxomicin significantly reduces CDI recurrence, especially for infections caused by non-North American Pulsed Field type 1 strains.
- The safety profiles of fidaxomicin and vancomycin were similar in this trial.
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...